

# Agostino Tafuri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1394927/publications.pdf>

Version: 2024-02-01

195  
papers

11,997  
citations

66343

42  
h-index

26613

107  
g-index

200  
all docs

200  
docs citations

200  
times ranked

16594  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2007, 1773, 1263-1284.   | 4.1  | 1,858     |
| 2  | Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid). <i>New England Journal of Medicine</i> , 1991, 324, 1385-1393.   | 27.0 | 1,226     |
| 3  | ICOS is essential for effective T-helper-cell responses. <i>Nature</i> , 2001, 409, 105-109.   | 27.8 | 629       |
| 4  | T Cell Awareness of Paternal Alloantigens During Pregnancy. <i>Science</i> , 1995, 270, 630-633.   | 12.6 | 524       |
| 5  | Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. <i>Aging</i> , 2011, 3, 192-222.  | 3.1  | 520       |
| 6  | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health. <i>Oncotarget</i> , 2011, 2, 135-164.  | 1.8  | 509       |
| 7  | Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology</i> , 2020, 7, e737-e745.               | 4.6  | 430       |
| 8  | Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. <i>Blood</i> , 2007, 110, 840-846.  | 1.4  | 419       |
| 9  | Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. <i>Leukemia</i> , 2008, 22, 686-707.   | 7.2  | 337       |
| 10 | Impaired fetal T cell development and perinatal lethality in mice lacking the cAMP response element binding protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 4481-4486.           | 7.1  | 287       |
| 11 | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. <i>Oncotarget</i> , 2012, 3, 1068-1111.  | 1.8  | 279       |
| 12 | Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2019, 20, 781-794. | 10.7 | 254       |
| 13 | Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.. <i>Oncotarget</i> , 2012, 3, 954-987.   | 1.8  | 244       |
| 14 | Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. <i>Blood</i> , 2004, 104, 1995-1999.   | 1.4  | 225       |
| 15 | Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. <i>Leukemia</i> , 2008, 22, 708-722.  | 7.2  | 222       |
| 16 | COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). <i>Journal of Hematology and Oncology</i> , 2021, 14, 168.   | 17.0 | 189       |
| 17 | Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. <i>Blood</i> , 1991, 77, 700-711.  | 1.4  | 183       |
| 18 | A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. <i>Blood</i> , 2005, 105, 3434-3441.   | 1.4  | 178       |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 19 | Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. <i>Leukemia</i> , 2009, 23, 25-42.   | 7.2  | 174       |
| 20 | Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias. <i>Blood</i> , 2015, 126, 1925-1929.  | 1.4  | 154       |
| 21 | GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. <i>Blood</i> , 2019, 134, 935-945.  | 1.4  | 148       |
| 22 | MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. <i>Leukemia</i> , 2012, 26, 778-787.  | 7.2  | 126       |
| 23 | Control of Neonatal Tolerance to Tissue Antigens by Peripheral T Cell Trafficking. , 1998, 282, 1338-1341.   |      | 119       |
| 24 | Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. <i>Blood</i> , 2006, 107, 473-479.              | 1.4  | 109       |
| 25 | Cycling Status of CD34+ Cells Mobilized Into Peripheral Blood of Healthy Donors by Recombinant Human Granulocyte Colony-Stimulating Factor. <i>Blood</i> , 1997, 89, 1189-1196.  | 1.4  | 106       |
| 26 | MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. <i>Blood</i> , 2002, 100, 974-981.  | 1.4  | 99        |
| 27 | Growth-Inhibitory and Antiangiogenic Activity of the MEK Inhibitor PD0325901 in Malignant Melanoma with or without BRAF Mutations. <i>Neoplasia</i> , 2009, 11, 720-W6.  | 5.3  | 87        |
| 28 | Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. <i>Drug Resistance Updates</i> , 2007, 10, 81-100.   | 14.4 | 74        |
| 29 | Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.   | 1.2  | 72        |
| 30 | Epidermolysis bullosa and embryonic lethality in mice lacking the multi-PDZ domain protein GRIP1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 6816-6821.                        | 7.1  | 63        |
| 31 | E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. <i>British Journal of Haematology</i> , 2003, 120, 484-487.  | 2.5  | 63        |
| 32 | Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34 <sup>+</sup> cell population with intrinsic resistance to imatinib. <i>Blood</i> , 2009, 114, 5191-5200. | 1.4  | 62        |
| 33 | COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. <i>British Journal of Haematology</i> , 2021, 195, 371-377.  | 2.5  | 56        |
| 34 | Emerging MEK inhibitors. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 203-223.  | 2.4  | 54        |
| 35 | The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. <i>Journal of Molecular Medicine</i> , 2012, 90, 667-679.                                   | 3.9  | 54        |
| 36 | Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg <sup>TM</sup> CMA-676). <i>British Journal of Haematology</i> , 2001, 115, 63-65.                         | 2.5  | 53        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice. <i>Blood</i> , 2012, 119, 217-226.   | 1.4 | 52        |
| 38 | Histopathological and molecular features of persistent polyclonal Bâ€cell lymphocytosis (PPBL) with progressive splenomegaly. <i>British Journal of Haematology</i> , 2009, 144, 726-731.  | 2.5 | 51        |
| 39 | Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells. <i>Blood</i> , 2006, 107, 3495-3502.  | 1.4 | 50        |
| 40 | Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. <i>Current Opinion in Investigational Drugs</i> , 2008, 9, 614-30.   | 2.3 | 50        |
| 41 | Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells. <i>Oncotarget</i> , 2017, 8, 49451-49469.  | 1.8 | 49        |
| 42 | Beyond Single Pathway Inhibition: MEK Inhibitors as a Platform for the Development of Pharmacological Combinations with Synergistic Anti-Leukemic Effects. <i>Current Pharmaceutical Design</i> , 2005, 11, 2779-2795.   | 1.9 | 48        |
| 43 | ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. <i>Blood</i> , 2007, 109, 5473-5476.   | 1.4 | 46        |
| 44 | Advances in Targeting Signal Transduction Pathways. <i>Oncotarget</i> , 2012, 3, 1505-1521.  | 1.8 | 41        |
| 45 | MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. <i>Blood</i> , 2007, 109, 2121-2129.   | 1.4 | 38        |
| 46 | Energetic mitochondrial failing in vitiligo and possible rescue by cardiolipin. <i>Scientific Reports</i> , 2017, 7, 13663.  | 3.3 | 38        |
| 47 | Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. <i>Oncotarget</i> , 2015, 6, 32089-32103.  | 1.8 | 36        |
| 48 | Partial deletions of long arm of chromosome 6: biologic and clinical implications in adult acute lymphoblastic leukemia. <i>Leukemia</i> , 2002, 16, 2055-2061.  | 7.2 | 35        |
| 49 | Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for âœverticalâ€and âœlateralâ€combination strategies. <i>Journal of Molecular Medicine</i> , 2012, 90, 1133-1144.  | 3.9 | 35        |
| 50 | Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFN±-Dendritic Cells and Rituximab: a Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 5231-5241.                        | 7.0 | 34        |
| 51 | Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy. <i>Current Pharmaceutical Design</i> , 2016, 22, 2358-2388.  | 1.9 | 34        |
| 52 | Proapoptotic Activity and Chemosensitizing Effect of the Novel Akt Inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan-2-amine (A443654) in T-Cell Acute Lymphoblastic Leukemia. <i>Molecular Pharmacology</i> , 2008, 74, 884-895. | 2.3 | 33        |
| 53 | Emerging Raf inhibitors. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 633-648.  | 2.4 | 33        |
| 54 | Targeting the Akt, GSK-3, Bcl-2 axis in acute myeloid leukemia. <i>Advances in Biological Regulation</i> , 2017, 65, 36-58.  | 2.3 | 33        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Prognostic value of rhodamine-efflux and MDR-1/P-170 expression in childhood acute leukemia. <i>Leukemia Research</i> , 1995, 19, 927-931.  | 0.8 | 32        |
| 56 | Transcriptomic and phospho-proteomic analyzes of erythroblasts expanded <i>in vitro</i> from normal donors and from patients with polycythemia vera. <i>American Journal of Hematology</i> , 2013, 88, 723-729.   | 4.1 | 32        |
| 57 | PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression. <i>Oncotarget</i> , 2015, 6, 15008-15021.   | 1.8 | 32        |
| 58 | Interleukin-9 stimulates the proliferation of human myeloid leukemic cells. <i>Blood</i> , 1996, 87, 3852-3859.   | 1.4 | 31        |
| 59 | Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy. <i>Blood</i> , 2019, 134, 229-229.                         | 1.4 | 30        |
| 60 | The Activity of Differentiation Factors Induces Apoptosis in Polyomavirus Large T-Expressing Myoblasts. <i>Molecular Biology of the Cell</i> , 1998, 9, 1449-1463.  | 2.1 | 29        |
| 61 | t(4;11)(q21;p15) translocation involving NUP98 and RAP1GDS1 genes: characterization of a new subset of T acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2000, 109, 788-793.   | 2.5 | 28        |
| 62 | The pan-class I phosphatidylinositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia. <i>Scientific Reports</i> , 2015, 5, 18137.   | 3.3 | 28        |
| 63 | CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. <i>Blood Cancer Journal</i> , 2020, 10, 96.                                 | 6.2 | 28        |
| 64 | A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. <i>Blood Advances</i> , 2022, 6, 327-338.   | 5.2 | 28        |
| 65 | Reduced susceptibility to apoptosis correlates with kinetic quiescence in disease progression of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2001, 113, 391-399.   | 2.5 | 26        |
| 66 | An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms. <i>Annals of Hematology</i> , 2015, 94, 771-777. | 1.8 | 25        |
| 67 | Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 705-714.   | 3.4 | 25        |
| 68 | The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling. <i>Experimental Hematology</i> , 2015, 43, 974-985.e1.  | 0.4 | 24        |
| 69 | Biological Aspects of mTOR in Leukemia. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2396.  | 4.1 | 24        |
| 70 | Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. <i>Cell Cycle</i> , 2012, 11, 4447-4461.   | 2.6 | 22        |
| 71 | Colony-Stimulating Factors (rhG-CSF, rhGM-CSF, rIL-3, and BCFG) Recruit Myeloblastic and Lymphoblastic Leukemic Cells and Enhance the Cytotoxic Effects of Cytosine-Arabinoside. <i>Hamatologie Und Bluttransfusion</i> , 1990, 33, 747-762.                                | 0.0 | 22        |
| 72 | Flt3L induces the ex-vivo amplification of umbilical cord blood committed progenitors and early stem cells in short-term cultures. <i>British Journal of Haematology</i> , 1999, 106, 133-141.  | 2.5 | 21        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasana) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study. <i>Blood</i> , 2018, 132, 767-767. | 1.4 | 21        |
| 74 | Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. <i>Advances in Enzyme Regulation</i> , 2008, 48, 113-135.   | 2.6 | 20        |
| 75 | Tramesan, a novel polysaccharide from <i>Trametes versicolor</i> . Structural characterization and biological effects. <i>PLoS ONE</i> , 2017, 12, e0171412.   | 2.5 | 20        |
| 76 | COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. <i>British Journal of Haematology</i> , 2022, 196, 559-565.  | 2.5 | 20        |
| 77 | Cell cycle regulation and induction of apoptosis by IL-6 variants on the multiple myeloma cell line XG-1. <i>Annals of Hematology</i> , 1999, 78, 13-18.   | 1.8 | 19        |
| 78 | Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells. <i>Blood</i> , 2009, 113, 1522-1525.   | 1.4 | 19        |
| 79 | Metabolic Reprogramming Promotes Myogenesis During Aging. <i>Frontiers in Physiology</i> , 2019, 10, 897.  | 2.8 | 19        |
| 80 | DNA and RNA flow cytometric study in multiple myeloma. Clinical correlations. <i>Cancer</i> , 1991, 67, 449-454.   | 4.1 | 18        |
| 81 | Outpatient management of acute promyelocytic leukemia after consolidation chemotherapy. <i>Leukemia</i> , 1999, 13, 514-517.   | 7.2 | 17        |
| 82 | Serum Free Light Chains Removal by HFR Hemodiafiltration in Patients with Multiple Myeloma and Acute Kidney Injury: a Case Series. <i>Kidney and Blood Pressure Research</i> , 2018, 43, 1263-1272.  | 2.0 | 17        |
| 83 | Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells. <i>Oncotarget</i> , 2017, 8, 76525-76557.  | 1.8 | 17        |
| 84 | Thrombopoietin and interleukin 11 have different modulatory effects on cell cycle and programmed cell death in primary acute myeloid leukemia cells. <i>Experimental Hematology</i> , 1999, 27, 1255-1263.   | 0.4 | 16        |
| 85 | Ogilvie's syndrome in acute myeloid leukemia: pharmacological approach with neostigmine. <i>Annals of Hematology</i> , 2001, 80, 614-616.  | 1.8 | 16        |
| 86 | SIRT5 Inhibition Induces Brown Fat-Like Phenotype in 3T3-L1 Preadipocytes. <i>Cells</i> , 2021, 10, 1126.  | 4.1 | 16        |
| 87 | Hyperspectral Raman imaging of human prostatic cells: An attempt to differentiate normal and malignant cell lines by univariate and multivariate data analysis. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2017, 173, 476-488.                   | 3.9 | 15        |
| 88 | A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review. <i>BMC Cancer</i> , 2019, 19, 50.   | 2.6 | 15        |
| 89 | Interleukin-11 induces proliferation of human T-cells and its activity is associated with downregulation of p27(kip1). <i>Haematologica</i> , 2002, 87, 373-80.  | 3.5 | 14        |
| 90 | Preclinical Antileukemia Activity of Tramesan: A Newly Identified Bioactive Fungal Metabolite. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-8.   | 4.0 | 13        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Gene signature and immune cell profiling by high-dimensional, single-cell analysis in COVID-19 patients, presenting Low T3 syndrome and coexistent hematological malignancies. <i>Journal of Translational Medicine</i> , 2021, 19, 139.  | 4.4 | 13        |
| 92  | Effects of IL-6 Variants in Multiple Myeloma: Growth Inhibition and Induction of Apoptosis in Primary Cells. <i>Leukemia and Lymphoma</i> , 2002, 43, 2369-2375.  | 1.3 | 12        |
| 93  | Functional and kinetic characterization of granulocyte colony-stimulating factor-primed CD34 <sup>+</sup> human stem cells. <i>British Journal of Haematology</i> , 2003, 123, 720-729.   | 2.5 | 12        |
| 94  | The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera. <i>Experimental Hematology</i> , 2017, 50, 53-76.  | 0.4 | 12        |
| 95  | High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias. <i>Annals of Hematology</i> , 2003, 82, 476-480.   | 1.8 | 11        |
| 96  | Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation. <i>Leukemia Research</i> , 2006, 30, 785-794.                                    | 0.8 | 11        |
| 97  | The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma. <i>Investigational New Drugs</i> , 2019, 37, 548-558.  | 2.6 | 10        |
| 98  | mTOR Regulation of Metabolism in Hematologic Malignancies. <i>Cells</i> , 2020, 9, 404.   | 4.1 | 10        |
| 99  | Hypoxia-inducible factor-1 $\alpha$ (Pro-582-Ser) polymorphism prevents iron deprivation in healthy blood donors. <i>Blood Transfusion</i> , 2013, 11, 553-7.   | 0.4 | 10        |
| 100 | Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience. <i>Hematological Oncology</i> , 2022, 40, 32-40.                                   | 1.7 | 10        |
| 101 | High stimulatory activity of dendritic cells from diabetes-prone BioBreeding/Worcester rats exposed to macrophage-derived factors.. <i>Journal of Clinical Investigation</i> , 1993, 91, 2040-2048.                                       | 8.2 | 9         |
| 102 | Interleukin-9 in Human Myeloid Leukemia Cells. <i>Leukemia and Lymphoma</i> , 1997, 26, 563-573.  | 1.3 | 8         |
| 103 | Myeloperoxidase gene expression in non-infant pro-B acute lymphoblastic leukaemia with or without ALL1/AF4 transcript. <i>British Journal of Haematology</i> , 2000, 111, 1065-1070.  | 2.5 | 8         |
| 104 | Trisomy 13 in a patient with common acute lymphoblastic leukemia: description of a case and review of the literature. <i>Cancer Genetics and Cytogenetics</i> , 2003, 144, 69-72.   | 1.0 | 7         |
| 105 | Aggressive lymphomas of the elderly: the DEVEC metronomic chemotherapy schedule fits the unfit. <i>British Journal of Haematology</i> , 2018, 183, 819-822.   | 2.5 | 7         |
| 106 | SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience. <i>HemaSphere</i> , 2020, 4, e483.   | 2.7 | 7         |
| 107 | Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront. <i>Leukemia and Lymphoma</i> , 2015, 56, 2206-2207. | 1.3 | 6         |
| 108 | Phosphoproteomic Landscaping Identifies Non-canonical cKIT Signaling in Polycythemia Vera Erythroid Progenitors. <i>Frontiers in Oncology</i> , 2019, 9, 1245.  | 2.8 | 6         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment. <i>Hematological Oncology</i> , 2020, 38, 189-196.   | 1.7 | 6         |
| 110 | Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage-colony-stimulating factor in combination with standard induction chemotherapy: Effect of granulocyte macrophage-colony-stimulating factor on white blood cell counts. <i>Medical and Pediatric Oncology</i> , 1992, 20, 18-22.    | 1.0 | 5         |
| 111 | Interleukin-3 priming in acute myeloid leukaemia patients. <i>British Journal of Haematology</i> , 1995, 91, 234-244.   | 2.5 | 5         |
| 112 | Splenic marginal zone lymphoma in a HIV-1 infected patient: evidence favouring a pathogenetic role of HIV-1 itself in the lymphomagenesis. <i>Infection</i> , 2013, 41, 255-258.  | 4.7 | 5         |
| 113 | Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region. <i>Frontiers in Oncology</i> , 2020, 10, 848.  | 2.8 | 5         |
| 114 | Successful Treatment of a Patient With Breast Implant-Associated Anaplastic Large Cell Lymphoma With Local Residual Disease. <i>Annals of Plastic Surgery</i> , 2021, Publish Ahead of Print, .   | 0.9 | 5         |
| 115 | Liposomal daunorubicin plus cytosine arabinoside for elderly patients with acute myeloid leukemia The gimema experience. <i>Experimental Hematology</i> , 2000, 28, 1501-1502.  | 0.4 | 4         |
| 116 | Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Simultaneous Inhibition of the Raf/MEK/ERK and BCL-2 Pathways. <i>Blood</i> , 2008, 112, 5161-5161.   | 1.4 | 4         |
| 117 | Isolated molecular relapse in FIP1L1-PDGFR $\alpha$ hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 1161-1163.  | 2.3 | 3         |
| 118 | A POPULATION-BASED STUDY ON MYELODYSPLASTIC SYNDROMES IN THE LAZIO REGION (ITALY), MEDICAL MISCODING AND 11-YEAR MORTALITY FOLLOW-UP: THE GRUPPO ROMANO-LAZIALE MIELODISPLASIE EXPERIENCE OF RETROSPECTIVE MULTICENTRIC REGISTRY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017046. | 1.3 | 3         |
| 119 | Complete response in advanced breast cancer patient treated with a combination of capecitabine, oral vinorelbine and dasatinib. <i>Experimental Hematology and Oncology</i> , 2018, 7, 2.   | 5.0 | 3         |
| 120 | Central nervous system immune reconstitution inflammatory syndrome after autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 268-271.  | 2.4 | 3         |
| 121 | Matched-Pair Analysis of Transplant from Haploidentical, Unmanipulated Bone Marrow Donor versus HLA Identical Sibling for Patients with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1113-1118.   | 2.0 | 3         |
| 122 | Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients. <i>Oncotarget</i> , 2018, 9, 21758-21769.   | 1.8 | 3         |
| 123 | Multi-omic approach identifies a transcriptional network coupling innate immune response to proliferation in the blood of COVID-19 cancer patients. <i>Cell Death and Disease</i> , 2021, 12, 1019.   | 6.3 | 3         |
| 124 | Combination Treatment of Acute Myeloblastic Leukemia with rhGM-CSF and Standard Induction Chemotherapy. <i>Cancer Investigation</i> , 1993, 11, 229-234.  | 1.3 | 2         |
| 125 | Effects of mast cell growth factor on ara-c mediated acute myeloid leukemia cell killing. <i>Stem Cells</i> , 1993, 11, 88-92.  | 3.2 | 2         |
| 126 | Thrombopoietin, Interleukin-11, and Early-Acting Megakaryocyte Growth Factors in Human Myeloid Leukemia Cells. <i>Leukemia and Lymphoma</i> , 2000, 40, 179-190.  | 1.3 | 2         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 127 | Apoptosis Susceptibility and Cell-Cycle Distribution in Cells from Myelodysplastic Syndrome Patients: Modulatory In-Vitro Effects of G-CSF and Interferon- $\gamma$ . <i>Leukemia and Lymphoma</i> , 2004, 45, 1437-1443.  | 1.3 | 2         |
| 128 | Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up. <i>Leukemia Research</i> , 2018, 69, 18-23.  | 0.8 | 2         |
| 129 | High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. <i>International Journal of Hematology</i> , 2020, 112, 141-146.   | 1.6 | 2         |
| 130 | Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols. <i>Acta Oncologica</i> , 2021, 60, 1520-1526.   | 1.8 | 2         |
| 131 | Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations. <i>Blood</i> , 2020, 136, 43-44.   | 1.4 | 2         |
| 132 | Protein Expression of p15 and p21 Plays an Unfavorable Prognostic Role in Adult Acute Lymphoblastic Leukemia (ALL) Patients Independently of Their Gene Promoter Methylation Status.. <i>Blood</i> , 2007, 110, 2802-2802.                                       | 1.4 | 2         |
| 133 | Targeting Survival Cascades Induced by Activation of Ras/Raf/MEK/ERK and PI3K/Akt Pathways to Sensitize Cancer Cells to Therapy. , 2008, , 81-114.   |     | 2         |
| 134 | Diagnostic Value of Minor Salivary Glands Biopsy in Systemic Amyloidosis. <i>Blood</i> , 2015, 126, 5381-5381.   | 1.4 | 2         |
| 135 | Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group. <i>Annals of Hematology</i> , 2022, 101, 1275-1282.                                     | 1.8 | 2         |
| 136 | Aberrant Proliferative and Apoptotic Pathways in Acute Lymphoblastic Leukemia (ALL): Molecular Therapies to Overcome Chemo-Resistance. , 2011, , .   |     | 1         |
| 137 | New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathways. , 2013, , 331-372.   |     | 1         |
| 138 | Residual Site Radiotherapy After Immunochemotherapy in Primary Mediastinal B-Cell Lymphoma: A Monoinstitutional Retrospective Study. <i>In Vivo</i> , 2020, 34, 1407-1413.   | 1.3 | 1         |
| 139 | Fatigue in newly diagnosed acute myeloid leukaemia: general population comparison and predictive factors. <i>BMJ Supportive and Palliative Care</i> , 2023, 13, e344-e351.   | 1.6 | 1         |
| 140 | Comparative Gene Profiling of Acute Myeloid Leukemia (AML) and Malignant Melanoma (MEL) Cell Lines Exposed to the MEK Inhibitor PD0325901 Reveals Common Effectors of the MEK/ERK Kinase Module.. <i>Blood</i> , 2007, 110, 3470-3470.                           | 1.4 | 1         |
| 141 | Exclusion Criteria In The Dasistnd and Enestnd Trials: Which Could Their Impact Be On The Front-Line Treatment Of a "Real-life" Patient Population With Chronic Myelogenous Leukemia?. <i>Blood</i> , 2013, 122, 4002-4002.                                      | 1.4 | 1         |
| 142 | The BCL-2 Antagonist ABT-737 Is Highly Effective on Primary Acute Lymphoblastic Leukemia Cells.. <i>Blood</i> , 2007, 110, 155-155.  | 1.4 | 1         |
| 143 | The AKT Inhibitor, A443654, Induces Cell Cycle Arrest, Apoptosis and Synergizes with Chemotherapeutic Drugs in Multi-Drug Resistant T-Cell Acute Lymphoblastic Leukemia - A Novel Agent for Therapy of Drug Resistant ALL.. <i>Blood</i> , 2007, 110, 3344-3344. | 1.4 | 1         |
| 144 | Development of Mek inhibition (MEK-I)-Based Therapeutic Strategies in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2008, 112, 860-860.   | 1.4 | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 145 | Bcl-2 and mTOR as Effective Targets for Molecular Therapy of Acute Lymphoblastic Leukemia. Blood, 2010, 116, 3228-3228.   | 1.4 | 1         |
| 146 | MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients.,. Blood, 2011, 118, 3793-3793.  | 1.4 | 1         |
| 147 | Targeting Metabolic Pathways for Leukemia Treatment. Blood, 2012, 120, 1371-1371.   | 1.4 | 1         |
| 148 | Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood, 1991, 77, 700-711.   | 1.4 | 1         |
| 149 | Application of the International Prognostic Score of Thrombosis for Essential Thrombocytemia(ET) (IPSET-Thrombosis) in a Cohort of ET Patients: Experience from Gruppo Laziale for Myeloproliferative Ph Negative Neoplasms. Blood, 2015, 126, 2821-2821. | 1.4 | 1         |
| 150 | Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Azacytidine Treatment. Blood, 2016, 128, 5544-5544.   | 1.4 | 1         |
| 151 | Deferasirox in the Treatment of Iron Overload during Myeloproliferative Neoplasms (MPN). Blood, 2016, 128, 5465-5465.   | 1.4 | 1         |
| 152 | Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols. Blood, 2019, 134, 3845-3845.   | 1.4 | 1         |
| 153 | CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program. Blood, 2021, 138, 1262-1262.   | 1.4 | 1         |
| 154 | Chronic Lymphocytic Leukemia Cells with Mutated Nfkbie Are Positively Selected By Microenvironmental Signals and Display Reduced Sensitivity to Ibrutinib Treatment. Blood, 2021, 138, 248-248.   | 1.4 | 1         |
| 155 | Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study. Blood, 2020, 136, 45-46.   | 1.4 | 1         |
| 156 | Sequential Pilot Studies of Intensive Postremission Chemotherapy for Acute Nonlymphocytic Leukemia. Annals of the New York Academy of Sciences, 1987, 511, 436-441.   | 3.8 | 0         |
| 157 | Sexual function with and without erythropoietin therapy. International Journal of Artificial Organs, 1992, 15, 440-441.   | 1.4 | 0         |
| 158 | Cell Kinetic, Molecular and Clinical Analysis of Growth Factor Sensitization of Myeloid Leukemia1. , 1994, , 112-136.   |     | 0         |
| 159 | SP253A NEW STRATEGY TO REMOVE SERUM FREE LIGHT CHAINS(SFLC)IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND ACUTE KIDNEY INJURY (AKI). Nephrology Dialysis Transplantation, 2015, 30, iii462-iii462.  | 0.7 | 0         |
| 160 | Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients. American Journal of Hematology, 2015, 90, E95-E96.  | 4.1 | 0         |
| 161 | Arrhythmias and Cardiogenic Shock: A Rare Disease Presentation of Diffuse Large B-Cell Lymphoma with Cardiac Involvement. Hemato, 2021, 2, 353-357.   | 0.6 | 0         |
| 162 | Breast Cancer Resistance Protein (BCRP) in Adult Acute Lymphoblastic Leukemia Patients.. Blood, 2004, 104, 1897-1897.   | 1.4 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 163 | Diagnostic Approach to CD5+/CD23+ Leukemic Non-Hodgkin Lymphomas Lacking Lymphnode Histopathology.. Blood, 2005, 106, 4690-4690.   | 1.4 | 0         |
| 164 | Molecular and Functional Effects of the Novel MEK Inhibitor PD0325901 in Preclinical Models of Human Leukemias.. Blood, 2006, 108, 254-254.  | 1.4 | 0         |
| 165 | Protein Expression and Methylation Status of the CKI p21, p15 and p16 in Adult Acute Lymphoblastic Leukemia (ALL) Patients: Prognostic Implications.. Blood, 2006, 108, 1843-1843.   | 1.4 | 0         |
| 166 | Histopathologic and Molecular Features of Persistent Polyclonal B-Cell Lymphocytosis Challenging the Benign Nature of the Disorder.. Blood, 2006, 108, 4612-4612.  | 1.4 | 0         |
| 167 | Lympho Node Enlargement in Adult™s Patients Referred to Hematologist: A Frequent Not Classified Clinical Problem. Results from a Retrospective Study.. Blood, 2006, 108, 2486-2486.  | 1.4 | 0         |
| 168 | JAK2 (V617F) Mutation Levels and Marrow Fibrosis in Patients Affected by Budd-Chiari Syndrome and Non-Cirrhotic Extra-Hepatic Portal Vein Obstruction.. Blood, 2007, 110, 4652-4652.                                       | 1.4 | 0         |
| 169 | Functional Effects of the Bcl-2/Bcl-xL Inhibitor ABT-737 on Primary Cells from Smoldering Multiple Myeloma.. Blood, 2007, 110, 4782-4782.  | 1.4 | 0         |
| 170 | Roles of Raf/MEK/ERK and PI3K/Akt/mTOR Pathways in Prevention of Apoptosis and Induction of Drug Resistance in Myeloid Hematopoietic Cells.. Blood, 2007, 110, 641-641.  | 1.4 | 0         |
| 171 | Parallel Signaling through PI3K/AKT/mTOR Mediates Resistance to MEK Inhibition in Preclinical Models of Acute Myeloid Leukemia (AML): Synergistic Effects of Combined MEK and mTOR Inhibition.. Blood, 2009, 114, 594-594. | 1.4 | 0         |
| 172 | Preclinical Study to Sensitize Acute Lymphoblastic Leukemia Primary Cells by Combined mTOR and BCL-2 Inhibition with CCI-779 and ABT-737.. Blood, 2009, 114, 985-985.  | 1.4 | 0         |
| 173 | Effect of a novel cross-talk mechanism on the RAF/MEK/ERK and PI3K/AKT/mTOR pathways in melanoma: Role of ERK-mediated suppression of PTEN expression.. Journal of Clinical Oncology, 2010, 28, 8574-8574.                 | 1.6 | 0         |
| 174 | A Retrospective Epidemiological Analysis of 1572 Cases of Ph1- Myeloproliferative Neoplasms (MPNs) From 9 Centers In the Latium: Preliminary Results. Blood, 2010, 116, 5065-5065.   | 1.4 | 0         |
| 175 | Pre Clinical mTOR-Inhibition of Acute Lymphoblastic Leukemia Cells Synergizes with Pro-Apoptotic Target Therapy Through Mcl-1 Down-Regulation,. Blood, 2011, 118, 3581-3581.   | 1.4 | 0         |
| 176 | Clinical Follow-up of Patients with Myeloproliferative Neoplasms Presenting Skin Ulcers During Treatment with Hydroxyurea. Blood, 2011, 118, 5157-5157.  | 1.4 | 0         |
| 177 | Clinical Features of Idiopathic Erythrocytosis Compared to Polycythemia Vera JAK-2 V617F Positive and Negative Patients. Blood, 2011, 118, 5172-5172.  | 1.4 | 0         |
| 178 | Proteomic Signature of CD34+ Cells From Chronic Myeloid Leukemia Patients. Blood, 2012, 120, 3733-3733.  | 1.4 | 0         |
| 179 | The Role of Previous Thrombotic Events in Patients with Essential Thrombocythemia: The Earlier the Worse?. Blood, 2012, 120, 5062-5062.  | 1.4 | 0         |
| 180 | Incidence of Late Chronic Anemia in Newly Diagnosed Patients with Chronic Myelogenous Leukemia Responsive to Imatinib. Blood, 2012, 120, 3769-3769.  | 1.4 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 181 | Transcriptosome and Phospho-Proteomic Analyses of Erythroblasts Expanded in Vitro From Normal Donors (ND) and From Patients with Polycythemia Vera (PV).. Blood, 2012, 120, 2860-2860.   | 1.4 | 0         |
| 182 | Differential Modulation Of cKIT Signaling By CD63 Dictates The Magnitude Of Response To Stem Cell Factor Of Erythroblasts From Adult Blood, Cord Blood and Polycythemia Vera. Blood, 2013, 122, 2850-2850.                               | 1.4 | 0         |
| 183 | Modulation Of The Glycolytic Metabolism In Acute Myeloid Leukemia Cells. Blood, 2013, 122, 5045-5045.  | 1.4 | 0         |
| 184 | Proteomic Profile Of CD34+ Cells From Chronic Myeloid Leukemia Patients and From Normal Donors. Blood, 2013, 122, 2712-2712.   | 1.4 | 0         |
| 185 | Incidence of Infectious Complications in MDS/AML Patients Treated with Azacitidine By the Italian Cooperative Groups Gruppo Romano MDS (GROM) and Basilicata MDS Registry. Blood, 2014, 124, 3265-3265.                                  | 1.4 | 0         |
| 186 | The JAK2 V617F Mutation Disrupts the Regulatory Activity Exerted By Calreticulin on the Glucocorticoid Receptor in Erythroid Cells. Blood, 2015, 126, 5216-5216.   | 1.4 | 0         |
| 187 | Targeting Glycolysis and MAPK Pathway: A Combined Pre-Clinical Approach on Acute Myeloid Leukemia. Blood, 2016, 128, 2751-2751.  | 1.4 | 0         |
| 188 | Phosphoproteomic Landscaping Unveils Constitutive cKIT Activation in Human Erythroblasts from Polycythemia Vera (PV) Patients. Blood, 2016, 128, 399-399.  | 1.4 | 0         |
| 189 | The Carboxy-Terminal Domain of Calreticulin (CALR) Exports the Glucocorticoid Receptor (GR) from the Nucleus to the Cytoplasm of Human Erythroid Cells Resetting Their Stress Response. Blood, 2016, 128, 545-545.                       | 1.4 | 0         |
| 190 | Essential Thrombocythemia: A Comparison of Overall and Thrombosis Free Survival in Two Discrete Periods of the First Decade of 2000. a Retrospective Analysis. Blood, 2016, 128, 5469-5469.  | 1.4 | 0         |
| 191 | DEVEC metronomic schedule for aggressive B and T-cell lymphomas.. Journal of Clinical Oncology, 2018, 36, 7563-7563.   | 1.6 | 0         |
| 192 | Real Life Use of Bendamustine Plus Rituximab Versus Chlorambucil Plus Rituximab As Front-Line Therapy for Elderly CLL Patients. Retrospective Multicenter Study in the Lazio Region. Blood, 2018, 132, 5550-5550.                        | 1.4 | 0         |
| 193 | High Response Rate in Relapsed/Refractory Follicular Lymphoma Following Personalised Immunotherapy with Intranodal IFN- $\alpha$ -Dendritic-Cell and Rituximab. Blood, 2018, 132, 5334-5334.   | 1.4 | 0         |
| 194 | Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas. Hematological Oncology, 2023, 41, 571-573. | 1.7 | 0         |
| 195 | Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical "Biological Entity?". Journal of Clinical Medicine, 2022, 11, 2596.   | 2.4 | 0         |